Stock prices in the live music industry sharply rose on Monday (November 9) following a breakthrough in the race to develop a COVID-19 vaccine.
Shortly after Pfizer and BioNTech announced that they had developed a vaccine that was found to be 90% effective in a trial of over 40,000 participants, live music stocks swiftly rose.
As well as market indexes from around the world experiencing a sharp rise, the stock prices for live music companies including Live Nation (+20.8%) and German concert promoter CTS Eventim (+23.5%) skyrocketed.
“Today is a great day for science and humanity," said Dr. Albert Bourla, Pfizer Chairman and CEO. "The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19. We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen."
Bouria added, With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis."
Worth over $50 billion, the global live music industry has faced unprecedented challenges since March.
Copyright Thrust Publishing Ltd. Permission to use quotations from this article is granted subject to appropriate credit being given to www.djmag.com as the source.